Boston Scientific Corporation (NYSE:BSX) UBS Global Healthcare Conference November 12, 2024 10:15 AM ET
Company Participants
Jonathan Monson – Senior Vice President, Investor Relations
Nick Spadea-Anello – VP & GM of Interventional Cardiology
Conference Call Participants
Danielle Antalffy – UBS
Danielle Antalffy
So good morning, everyone. Thanks so much for joining us. And for those who don’t know me, I’m Danielle Antalffy, I’m the U.S. Medtech analyst here at UBS. Very lucky to have with us Boston Scientific. We’ve got the Head of Investor Relations, Jon Monson. Somewhere out there, we have the Head of the EP business, Nick Spadea-Anello. Did I pronounced it correctly?
So I mean, while we’re searching for Nick, let’s maybe start with the big question on everyone’s mind for Boston Scientific is how to think about growth for 2025. You guys have had a phenomenal year-to-date 2024. You raised guidance recently. How conceptually, appreciating you’re not going to give guidance here on this podium today. How should we think about the puts and takes to 2025? And can you sustain the momentum? And the question I get asked pretty consistently is, can you still grow double digits?
Jonathan Monson
Sure. Well, first, Danielle, thanks so much for having us here today, and thanks, everyone, for your interest in Boston Scientific.
And maybe if I could, let me start with 2024. We had a tremendous quarter here in Q3, and we’re on track for a tremendous year in ’24. So just to recap, we grew our organic revenue 18.2% here in the third quarter, delivered adjusted operating margin of 27.2%, and grew our EPS 27% in the quarter. And then for the year, we’ve raised our guidance to 15% organic revenue growth. We expect to expand our operating margin 70 basis points to approximately 27% op margin, and guiding to 20% to 21% adjusted EPS growth. And that’s on top of a strong year in
Read the full article here
